HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 1,381-1,392 of 4,505
Drug study icon
Not recruitingEUCTR 2020-000102-28

Does the glucagon-like peptide-1 receptor agonist semaglutide prevent deterioration in glycaemic control in prediabetic or diabetic patients with schizophrenia spectrum disorder treated with the an...

This study isn't currently recruiting.

This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.

In Copenhagen Oe
SchizophreniaHistorical research record
Countries
Denmark
Sponsor
Mental Healt Center Copenhagen
Behavioral study icon
CompletedNCT02283437

A Problem-solving Based Bibliotherapy Program for Family Caregivers in Schizophrenia

Official study title

A Randomized Controlled Trial of Problem-solving Based Bibliotherapy Program for Family Caregivers of People With Schizophrenia Spectrum Disorders

This study has finished and is no longer accepting participants.

Multiple locations, including Mong Kok
SchizophreniaBehavioural studyAges 18–64
Countries
China
Sponsor
Chinese University of Hong Kong
Drug study icon
CompletedNCT06068465

Safety study of safety and Efficacy of Pimavanserin in Schizophrenia

Official study title

A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease

This study has finished and is no longer accepting participants.

Multiple locations, including Hefei
SchizophreniaMedication studyAges 40+
Countries
China
Sponsor
Tasly Pharmaceutical Group Co., Ltd
Drug study icon
WithdrawnNCT05344365

Iloperidone for Schizophrenia

Official study title

An Open-label, Sequential Cohorts, Flexible Dose Study to Evaluate the Tolerability, Safety and Pharmacokinetics of Iloperidone in Elderly Patients With Parkinson's Disease Psychosis (PDP)

This study was withdrawn before enrollment.

In St. Petersburg
SchizophreniaMedication studyAges 65+
Countries
United States
Sponsor
Vanda Pharmaceuticals
Drug study icon
CompletedNCT02969369

Safety study of SEP-363856 in Schizophrenia

Official study title

A Multicenter Randomized Double-blind Followed by an Open-label Extension Study to Evaluate the Efficacy, Safety, and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

This study has finished and is no longer accepting participants.

Multiple locations, including Fresno
SchizophreniaMedication studyAges 55–105
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.